Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
Profitability Metrics
Gross Margin
93.26%
Operating Margin
-6.44%
Net Margin
98.77%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
139.51%
Income Tax Rate
0.00%
EPS
3.3100000000
Balance Sheet Analysis
Current Ratio
0.00
Cash Ratio
4.48
Working Capital
$-14.71M
Debt to Equity
1.39
Debt to Assets
57.21%
Equity Ratio
41.18%
Cash Flow Analysis
Operating Cash Flow Ratio
52.31%
Free Cash Flow Ratio
52.31%
CapEx to Revenue
0.00%
Dividends Paid
$33.92M
Stock Buybacks
No buybacks
Total Shareholder Returns
$33.92M
Cash Position Change
28.25%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 28.00%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
249.88%
Net Income
244.78%
EPS
202.80%
Operating Income
90.56%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-10.58%
Operating Cash Flow
127.44%
Free Cash Flow
127.44%
Balance Sheet Health
Assets
6.09%
Debt
0.08%
Book Value per Share
-9.68%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
28.00%
Shares Outstanding
40.73%
Long Term Trends
3Y Revenue/Share
53.05%
5Y Revenue/Share
0.00%
3Y Dividend/Share
245.40%
5Y Dividend/Share
0.00%